 For 74 participant the reason for first treatment modification was unblinded and switched as a consequence of the DSMB results 33 on EFV, ABC3TC, and placebo FTCTDF arm; 1 on RTV-boosted ATV, FTCTDF, and placebo ABC3TC arm; and 40 on RTV-boosted ATV, ABC3TC, and placebo FTCTDF arm. 